Cellebrite Di Stock Performance
| CLBT Stock | USD 18.25 0.97 5.61% |
The firm shows a Beta (market volatility) of -0.2, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Cellebrite are expected to decrease at a much lower rate. During the bear market, Cellebrite is likely to outperform the market. At this point, Cellebrite DI has a negative expected return of -0.12%. Please make sure to confirm Cellebrite's value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Cellebrite DI performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Cellebrite DI has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's fundamental drivers remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
| Begin Period Cash Flow | 189.5 M | |
| Free Cash Flow | 118.3 M |
Cellebrite |
Cellebrite Relative Risk vs. Return Landscape
If you would invest 2,023 in Cellebrite DI on December 17, 2024 and sell it today you would lose (198.00) from holding Cellebrite DI or give up 9.79% of portfolio value over 90 days. Cellebrite DI is currently does not generate positive expected returns and assumes 3.0302% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Cellebrite, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cellebrite Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cellebrite's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cellebrite DI, and traders can use it to determine the average amount a Cellebrite's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0404
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLBT |
Estimated Market Risk
| 3.03 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cellebrite is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cellebrite by adding Cellebrite to a well-diversified portfolio.
Cellebrite Fundamentals Growth
Cellebrite Stock prices reflect investors' perceptions of the future prospects and financial health of Cellebrite, and Cellebrite fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cellebrite Stock performance.
| Return On Equity | -1.53 | ||||
| Return On Asset | 0.0581 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 3.49 B | ||||
| Shares Outstanding | 214.84 M | ||||
| Price To Earning | 82.18 X | ||||
| Price To Book | 11.69 X | ||||
| Price To Sales | 9.77 X | ||||
| Revenue | 401.2 M | ||||
| EBITDA | (265.38 M) | ||||
| Cash And Equivalents | 142.51 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 10.97 M | ||||
| Book Value Per Share | 1.44 X | ||||
| Cash Flow From Operations | 126.84 M | ||||
| Earnings Per Share | (1.35) X | ||||
| Total Asset | 690.57 M | ||||
| Retained Earnings | (164.86 M) | ||||
About Cellebrite Performance
Assessing Cellebrite's fundamental ratios provides investors with valuable insights into Cellebrite's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Cellebrite is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation. Cellebrite operates under SoftwareInfrastructure classification in the United States and is traded on NASDAQ Exchange. It employs 900 people.Things to note about Cellebrite DI performance evaluation
Checking the ongoing alerts about Cellebrite for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cellebrite DI help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cellebrite DI generated a negative expected return over the last 90 days | |
| Cellebrite DI has high historical volatility and very poor performance | |
| Cellebrite DI has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 401.2 M. Net Loss for the year was (283.01 M) with profit before overhead, payroll, taxes, and interest of 338.61 M. | |
| About 50.0% of the company shares are held by company insiders |
- Analyzing Cellebrite's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cellebrite's stock is overvalued or undervalued compared to its peers.
- Examining Cellebrite's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cellebrite's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cellebrite's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cellebrite's stock. These opinions can provide insight into Cellebrite's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Cellebrite Stock Analysis
When running Cellebrite's price analysis, check to measure Cellebrite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellebrite is operating at the current time. Most of Cellebrite's value examination focuses on studying past and present price action to predict the probability of Cellebrite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellebrite's price. Additionally, you may evaluate how the addition of Cellebrite to your portfolios can decrease your overall portfolio volatility.